Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX – Get Free Report) Director Deborah Andrews purchased 25,000 shares of the stock in a transaction on Monday, November 16th. The shares were bought at an average cost of $0.80 per share, for a total transaction of $20,000.00. Following the transaction, the director directly owned 40,578 shares in the company, valued at approximately $32,462.40. The trade was a 160.48% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Lineage Cell Therapeutics Trading Down 2.2%
Shares of Lineage Cell Therapeutics stock opened at $0.82 on Friday. Lineage Cell Therapeutics, Inc. has a 12-month low of $0.77 and a 12-month high of $1.99. The business’s 50 day moving average is $0.98 and its 200-day moving average is $1.28.
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX – Get Free Report) last released its earnings results on Thursday, November 12th. The company reported ($0.03) earnings per share for the quarter, meeting the consensus estimate of ($0.03). The business had revenue of $1.43 million during the quarter, compared to analysts’ expectations of $2.32 million. Lineage Cell Therapeutics had a net margin of 16.18% and a return on equity of 3.16%. On average, equities research analysts expect that Lineage Cell Therapeutics, Inc. will post -0.04 EPS for the current year.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently made changes to their positions in LCTX. StoneX Group Inc. increased its holdings in shares of Lineage Cell Therapeutics by 74.9% during the 3rd quarter. StoneX Group Inc. now owns 29,747 shares of the company’s stock worth $30,000 after acquiring an additional 12,739 shares during the last quarter. Equitable Holdings Inc. acquired a new stake in Lineage Cell Therapeutics during the 2nd quarter valued at $39,000. Two Sigma Securities LLC boosted its position in Lineage Cell Therapeutics by 85.4% during the second quarter. Two Sigma Securities LLC now owns 37,793 shares of the company’s stock worth $50,000 after purchasing an additional 17,403 shares during the period. State of Wyoming bought a new position in Lineage Cell Therapeutics during the second quarter worth $57,000. Finally, Cibc World Market Inc. bought a new position in Lineage Cell Therapeutics during the second quarter worth $62,000. 62.47% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
Separately, Raymond James Financial restated a “market perform” rating on shares of Lineage Cell Therapeutics in a research note on Friday, November 13th. Four analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $6.25.
Get Our Latest Research Report on LCTX
About Lineage Cell Therapeutics
Lineage Cell Therapeutics is a biotechnology company developing cell-based therapies for serious medical conditions. The company uses its cell therapy platform to create and manufacture specialized human cells intended to replace or support damaged cells and tissues. Its programs include OpRegen, a retinal pigment epithelial cell therapy being developed for retinal diseases; OPC1, an oligodendrocyte progenitor cell therapy for spinal cord injury; ANP1, an auditory neuron progenitor cell program for hearing loss; and VAC2, a cell-based cancer immunotherapy.
Read More
- Five stocks we like better than Lineage Cell Therapeutics
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Lineage Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lineage Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
